Eli Lilly and Company (LLY) Stock Price, News & Analysis

Company Overview

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A. Ricks.

Lilly’s core activities center on discovery and development of small-molecule and biologic therapies across multiple therapeutic areas, including diabetes and metabolic disease, oncology, neuroscience, immunology and pain. Its commercial portfolio includes longstanding and well-known medicines as well as newer specialty products; examples of medicines associated with the company include Humalog (insulin), duloxetine (Cymbalta), fluoxetine (Prozac), the GLP-1/GIP receptor-directed agent tirzepatide (marketed for type 2 diabetes) and a range of oncology and migraine treatments such as Alimta, Verzenio and Emgality. The company combines internal discovery programs with external collaborations and licensing arrangements to broaden its pipeline and commercial reach.

Research and development is a central focus for Lilly, with substantial investment in clinical development, regulatory activities and manufacturing scale-up to move novel candidates from laboratory to clinic. The company operates multiple research centers and manufacturing facilities and emphasizes biopharma capabilities, including biologics and antibody-based therapies. Its pipeline spans early-stage discovery through late-stage clinical trials, targeting both established and emerging disease areas.

Strategically, Eli Lilly emphasizes innovation in chronic and complex diseases, expanding patient access to new treatments and pursuing global commercialization. The company’s operations combine proprietary R&D, manufacturing infrastructure and global commercial teams to deliver therapies to healthcare providers and patients, while also engaging in partnerships and licensing to accelerate development and distribution.

Key Stats

• Today's Range: $1,230.95 to $1,262.14
• 50-Day Range: $1,098.78 to $1,280.62
• 52-Week Range: $694.23 to $1,292.65
• Volume: 1.66 million shs
• Average Volume: 2.86 million shs
• Market Capitalization: $1.17 trillion
• P/E Ratio: 41.88
• Dividend Yield: 0.55%
• Price Target: $1,292.18
• Consensus Rating: Moderate Buy

Eli Lilly and Company Stock Analysis - MarketRank™

Eli Lilly and Company scored higher than 93% of companies evaluated by MarketBeat, and ranked 27th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 24 buy ratings, 4 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Eli Lilly and Company is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Eli Lilly and Company has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 26.19%

Earnings Growth

Earnings for Eli Lilly and Company are expected to grow by 26.19% in the coming year, from $36.35 to $45.87 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eli Lilly and Company is 41.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eli Lilly and Company is 41.88, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.56.

Price to Earnings Growth Ratio

Eli Lilly and Company has a PEG Ratio of 1.48. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Eli Lilly and Company has a P/B Ratio of 44.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.97% of the float of Eli Lilly and Company has been sold short.

Short Interest Ratio / Days to Cover

Eli Lilly and Company has a short interest ratio ("days to cover") of 3.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eli Lilly and Company has recently decreased by 11.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Eli Lilly and Company has a dividend yield of 0.55%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Eli Lilly and Company has been increasing its dividend for 11 years.

Dividend Coverage

The dividend payout ratio of Eli Lilly and Company is 23.22%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 15.09% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.07

News Sentiment

Eli Lilly and Company has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 149 news articles for Eli Lilly and Company this week, compared to 11 articles on an average week.

Search Interest

134 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

163 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 298% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,958,170.00 in company stock.

Percentage Held by Insiders

0.14% of the stock of Eli Lilly and Company is held by insiders.

Percentage Held by Institutions

82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 6/10 Dividend: 5/15/2026
• Ex-Dividend for 6/10 Dividend: 5/15/2026
• Dividend Payable: 6/10/2026
• Last Earnings: 8/05/2026
• Record date for 9/10 Dividend: 8/14/2026
• Ex-Dividend for 9/10 Dividend: 8/14/2026
• Today: 8/24/2026
• Dividend Payable: 9/10/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:LLY
• CIK: 59478
• Web: www.lilly.com
• Phone: (317) 276-2000
• Fax: 317-276-4878
• Employees: 50,000
• Year Founded: 1876

Price Target and Rating

• Average Price Target for Eli Lilly and Company: $1,292.18
• High Price Target: $1,600.00
• Low Price Target: $850.00
• Potential Upside/Downside: +3.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 30 Analysts

Profitability

• EPS (Trailing Twelve Months): $29.80
• Trailing P/E Ratio: 41.88
• Forward P/E Ratio: 34.33
• P/E Growth: 1.48
• Net Income: $20.64 billion
• Net Margins: 33.53%
• Pretax Margin: 42.17%
• Return on Equity: 97.83%
• Return on Assets: 23.23%

Debt

• Debt-to-Equity Ratio: 1.41
• Current Ratio: 1.35
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $79.67 billion
• Price / Sales: 14.75
• Cash Flow: $24.99 per share
• Price / Cash Flow: 49.94
• Book Value: $28.07 per share
• Price / Book: 44.46

Miscellaneous

• Outstanding Shares: 941,357,000
• Free Float: 940,039,000
• Market Cap: $1.17 trillion
• Optionable: Optionable
• Beta: 0.51